The Novel VEGF121-VEGF165 Fusion Attenuates Angiogenesis and Drug Resistance via Targeting VEGFR2-HIF-1α-VEGF165/Lon Signaling Through PI3K-AKT-mTOR Pathway.

abstract：:Preferentially expressed antigen in melanoma (PRAME) is the best characterized member of the PRAME family of leucine-rich repeat (LRR) proteins. Mammalian genomes contain multiple members of the PRAME family whereas in other vertebrate genomes only one PRAME-like LRR protein was identified. PRAME is a cancer/testis an...

journal_title：Current cancer drug targets

authors： Hermes N,Kewitz S,Staege MS

更新日期：2016-01-01 00:00:00

abstract：:Inactivation of the FHIT and TP53 genes is frequently observed in primary non-small cell lung cancers (NSCLC) and cell lines and may contribute to resistance to apoptotic stimuli elicited by various anti-tumor drugs. To evaluate a possible relationship between FHIT and TP53 status and response to platinum-analogue reg...

journal_title：Current cancer drug targets

authors： Cortinovis DL,Andriani F,Livio A,Fabbri A,Perrone F,Marcomini B,Pilotti S,Mariani L,Bidoli P,Bajetta E,Roz L,Sozzi G

更新日期：2008-08-01 00:00:00

abstract：:The anticancer properties of histone deacetylase inhibitors have been known for some time. However, it is only recently that the functional identities of the intracellular targets mediating the anticancer properties have started to be revealed. These targets appear to play significant roles in cell cycle control, apop...

journal_title：Current cancer drug targets

authors： Gabrielli BG,Johnstone RW,Saunders NA

更新日期：2002-12-01 00:00:00

abstract：:The histone deacetylase inhibitors are a new class of cytostatic agents that inhibit the proliferation of tumor cells in culture and in vivo by inducing cell cycle arrest, differentiation and/or apoptosis. Histone acetylation and deacetylation play important roles in the modulation of chromatin topology and the regula...

journal_title：Current cancer drug targets

authors： Vigushin DM,Coombes RC

更新日期：2004-03-01 00:00:00

abstract：:Targeted therapies focus on signaling pathways in cancer cells and other molecular processes involved in oncogenesis. Recent approaches affect the following major groups: the epidermal growth factor receptor (EGFR)-family, angiogenesis, the eicosanoid pathway, the PKC/ Ras/ MAPK pathway, the proteasome and inducers of...

journal_title：Current cancer drug targets

authors： Auberger J,Loeffler-Ragg J,Wurzer W,Hilbe W

更新日期：2006-06-01 00:00:00

abstract：:Prostate cancer is the most frequently diagnosed tumor in industrialized countries. Endocrine therapy, which is based on interference with androgen signaling is only palliative. Drugs used in prostate cancer therapy are luteinizing hormone releasing hormone (LHRH) agonists and antiandrogens. Application of LHRH agonis...

journal_title：Current cancer drug targets

authors： Culig Z,Bartsch G,Hobisch A

更新日期：2004-08-01 00:00:00

abstract：:Hepatocellular carcinoma (HCC), considered to be one of the most lethal cancers with almost > 1 million deaths reported annually worldwide, remains a devastating disease with no known effective cure. Hence, chemopreventive strategies come into play, offering an effective and safe mode of treatment, ideal to ward off p...

journal_title：Current cancer drug targets

authors： Thoppil RJ,Bhatia D,Barnes KF,Haznagy-Radnai E,Hohmann J,Darvesh AS,Bishayee A

更新日期：2012-11-01 00:00:00

abstract：:Malignant gliomas are frequently chemoresistant and this resistance seems to depend on at least two mechanisms. First, the poor penetration of many anticancer drugs across the blood-brain barrier (BBB), the blood-cerebrospinal fluid barrier (BCSFB) and blood-tumor barrier (BTB), due to their interaction with several A...

journal_title：Current cancer drug targets

authors： Declèves X,Amiel A,Delattre JY,Scherrmann JM

更新日期：2006-08-01 00:00:00

abstract：:Gardenia, the fruit of Gardenia jasminoides Ellis, has been widely used to treat liver and gall bladder disorders in Chinese medicine. It has been shown recently that geniposide, the main ingredient of Gardenia Fructus, exhibits the anti-tumor effect. In this review, we discuss the anti-tumor effect and possible mecha...

journal_title：Current cancer drug targets

authors： Peng CH,Huang CN,Wang CJ

更新日期：2005-06-01 00:00:00

abstract：:UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase-6 (pp-GalNAc-T6) is a member of the N-acetyl-D-galactosamine transferase family. It catalyzes the addition of N-acetyl-D-galactosamine to proteins, often the first step in O-glycosylation of proteins. Glycosylated proteins play important role...

journal_title：Current cancer drug targets

authors： Banford S,Timson DJ

更新日期：2017-01-01 00:00:00

abstract：:Androgen deprivation therapy has been the major treatment for advanced prostate cancer (PCa) and has shown to prolong life. However, remissions are temporary and patients almost inevitably progress to become castration-resistant prostate cancer (CRPC). CRPC is almost incurable even when treated with docetaxel that may...

journal_title：Current cancer drug targets

authors： Donkena KV,Yuan H,Young CY

更新日期：2010-06-01 00:00:00

abstract：:Scaffold-based analogs of cinnamic acid benzyl amide (CABA) exhibit pleiotropic effects in cancer cells, and their exact molecular mechanism of action is under investigation. The present study is part of our systemic analysis of interactions of CABA analogs with their molecular targets. These compounds were shown to i...

journal_title：Current cancer drug targets

authors： Mielecki M,Milner-Krawczyk M,Grzelak K,Mielecki D,Krzysko KA,Lesyng B,Priebe W

更新日期：2014-01-01 00:00:00

abstract：:Cancer drug therapy is undergoing a major transition from the previous pregenomic cytotoxic era to the new postgenomic era. Future mechanism-based therapeutic agents will increasingly be designed to act on molecular targets that are causally involved in the malignant progression of human cancers. Such agents are predi...

journal_title：Current cancer drug targets

authors： Workman P

更新日期：2001-05-01 00:00:00

abstract：:Ovarian cancer is a leading cause of death worldwide from gynecological malignancies, mainly because there are few early symptoms and the disease is generally diagnosed at an advanced stage. In addition, despite the effectiveness of cytoreductive surgery for ovarian cancer and the high response rates to chemotherapy, ...

journal_title：Current cancer drug targets

authors： Liang Z,Lu Z,Zhang Y,Shang D,Li R,Liu L,Zhao Z,Zhang P,Lin Q,Feng C,Zhang Y,Liu P,Tu Z,Liu H

更新日期：2019-01-01 00:00:00

abstract：:Bisphosphonates are the standard of care for preventing skeletal morbidity and treating hypercalcemia of malignancy in patients with bone metastases. Zoledronic acid (intravenous; 4 mg monthly) is approved to prevent skeletal-related events (SREs) in patients with bone metastases from several tumor types, and can impr...

journal_title：Current cancer drug targets

authors： Gnant M

更新日期：2009-11-01 00:00:00

abstract：:Autophagy is an intracellular lysosomal/vacuolar degradation system, in which the inner cytoplasmic cell membrane is degraded by the lysosomal hydrolases, followed by the resulting products released back into the cytosol. It is involved in many physiological processes which are crucial for cell growth and survival. Ho...

journal_title：Current cancer drug targets

authors： Zhou X,Yue GG,Tsui SK,Pu J,Fung KP,Lau CB

更新日期：2018-01-01 00:00:00

abstract：:The epidermal growth factor (EGFR) and its receptor were discovered nearly 40 years ago. Over the past decade interruption of this pathway has been exploited in the treatment of various solid tumors. Antibodies that interfere with ligand binding to and dimerization of the EGFR (and small molecules that inhibit the EGF...

journal_title：Current cancer drug targets

authors： Astsaturov I,Cohen RB,Harari P

更新日期：2007-11-01 00:00:00

abstract：:Despite advances in multidisciplinary approaches, the prognosis for most patients with malignant gliomas is poor. Malignant gliomas are highly vascularized tumors with elevated expression of vascular endothelial growth factor (VEGF), an important mediator of angiogenesis. Recent studies of bevacizumab, an anti-VEGF mo...

journal_title：Current cancer drug targets

authors： Soffietti R,Trevisan E,Bertero L,Bosa C,Ruda R

更新日期：2012-03-01 00:00:00

abstract：BACKGROUND:Improving poorly soluble drugs into druggability was a major problem faced by pharmaceutists. Nanosuspension can improve the druggability of insoluble drugs by improving the solubility, chemical stability and reducing the use of additives, which provided a new approach for the development and application of ...

journal_title：Current cancer drug targets

authors： Cao Y,Wei Z,Li M,Wang H,Yin L,Chen D,Wang Y,Chen Y,Yuan Q,Pu X,Zong L,Duan S

更新日期：2019-01-01 00:00:00

abstract：:Breast cancer is one of the most common malignancies among women, representing nearly 30% of newly diagnosed cancers every year. Till date, various therapeutic interventions, including surgery, chemotherapy, hormonal therapy, and radiotherapy are available and are known to cause a significant decline in the overall mo...

journal_title：Current cancer drug targets

authors： Siddiqui JA,Singh A,Chagtoo M,Singh N,Godbole MM,Chakravarti B

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:MicroRNA (miRNA) therapy, which was widely considered to treat a series of cancer, has been confronted with numerous obstacles to being delivered into target cells because of its easy biodegradation and instability. METHODS:In this research, we successfully constructed 11-mercaptoundecanoic acid modified go...

journal_title：Current cancer drug targets

authors： Yan LJ,Guo XH,Wang WP,Hu YR,Duan SF,Liu Y,Sun Z,Huang SN,Li HL

更新日期：2019-01-01 00:00:00

abstract：:The evolution of genomic research enabled the genetic and molecular profiling of breast cancer and revealed the profound complexity and heterogeneity of this disease. Subtypes of breast cancer characterized by mutations and/or amplifications of some proto-oncogenes are associated with an increased rate of recurrence a...

journal_title：Current cancer drug targets

authors： Guerram M,Hamdi AM,Zhang LY,Jiang Z

更新日期：2017-01-01 00:00:00

abstract：:One of the challenges of cancer therapeutics is to discover targets unique to the tumor cell population. Constitutively activated tyrosine kinases play a role in the malignant phenotype in a number of different cancers. While the kinases may be present in the normal cell, the cancer cell is often dependent upon the ac...

journal_title：Current cancer drug targets

authors： Ritchie E,Nichols G

更新日期：2006-12-01 00:00:00

abstract：:Malignant brain tumors including primary brain tumors (e.g., glioblastoma multiforme) and metastases, are aggressive and lethal entities for the majority of affected patients. Current standard treatments involving combinations of surgery, radiotherapy and systemic chemotherapy offer only modest improvements in surviva...

journal_title：Current cancer drug targets

authors： Drapeau A,Fortin D

更新日期：2015-01-01 00:00:00

abstract：:Tumor heterogeneity within various cancer types including breast carcinoma is pivotal in the manifestations of tumor hallmarks. Tumor heterogeneity is seen as a common landscape where intra-tumoral components including cellular and non-cellular factors create an interface with outside environment that leads to the uni...

journal_title：Current cancer drug targets

authors： Tandon I,Sharma NK

更新日期：2019-01-01 00:00:00

abstract：:AKT is a central signaling molecule in regulating cell survival, proliferation, tumor growth and angiogenesis. Upstream components of AKT signaling pathway such as PI3K, PTEN, and Ras are commonly mutated in many human cancers. Recently it is found that AKT plays an important role in regulating normal vascularization ...

journal_title：Current cancer drug targets

authors： Jiang BH,Liu LZ

更新日期：2008-02-01 00:00:00

abstract：:Targets for cancer therapy are conventionally selected by identification of molecules acting downstream of established tumour suppressors and oncoproteins, such as p53, c-Myc and Ras. However, the forward genetics approach provides an alternative, conceptually distinct, strategy for identifying target molecules de nov...

journal_title：Current cancer drug targets

authors： Mourtada-Maarabouni M,Watson D,Munir M,Farzaneh F,Williams GT

更新日期：2013-01-01 00:00:00

abstract：:Oncolytic viruses can selectively replicate in and lead to tumor cell lysis with minimal infection/replication potential in adjoining non-neoplastic tissue. Because of paramount safety concerns, first-generation oncolytic viruses were designed to be significantly attenuated in their lytic potential. Results from recen...

journal_title：Current cancer drug targets

authors： Hardcastle J,Kurozumi K,Chiocca EA,Kaur B

更新日期：2007-03-01 00:00:00

abstract：:The capacity to induce new blood vessel formation or to repair damaged vessels is an attractive idea that has, for a long time, captured the attention and imagination of researchers. Beside the identification of the pro-angiogenic growth factors and their counterpart inhibitors, the discovery of endothelial progenitor...

journal_title：Current cancer drug targets

authors： Pasquier E,Dias S

更新日期：2010-12-01 00:00:00

abstract：:Copper is a trace element which is tightly regulated in mammals and lower animals. Disruptions of copper homeostasis in humans are rare and they cause serious disorders such as Wilson's disease and Menke's disease. Copper plays an important role in promoting physiological and malignant angiogenesis. Formation of new b...

journal_title：Current cancer drug targets

authors： Goodman VL,Brewer GJ,Merajver SD

更新日期：2005-11-01 00:00:00